{"id":"W3031273809","doi":"10.1200/jco.2020.38.15_suppl.8519","title":"DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"GlaxoSmithKline","keywords":"Medicine; Renal function; Internal medicine; Gastroenterology; Tolerability; Neutropenia; Anemia; Creatinine; Population; Urology; Surgery; Adverse effect; Toxicity","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002701545,0.0004660806,0.001289571,0.0002881555,0.000132761,0.0006150986,0.0005294409,0.000534636,0.002090117],"category_scores_gemma":[0.001426347,0.0002962558,0.002140478,0.0003502883,0.0003343047,0.000734729,0.0005634102,0.001103346,0.0003084736],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001033249,"about_ca_system_score_gemma":0.001012998,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007360321,"about_ca_topic_score_gemma":0.002380533,"domain_scores_codex":[0.9991523,0.0004915308,0.00005605986,0.0001221467,0.00007519832,0.0001028176],"domain_scores_gemma":[0.9991523,0.0002055226,0.0002819516,0.0000624742,0.00004517537,0.000252635],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7971265,0.003258228,0.06239109,0.001424193,0.005688786,0.0002531572,0.0001688619,0.003125282,0.007768408,0.0002358368,0.003550892,0.1150089],"study_design_scores_gemma":[0.4109482,0.3418886,0.2139949,0.000249909,0.007277241,0.001092341,0.0002308284,0.005641709,0.004936633,0.0008138546,0.01282199,0.0001037425],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9909415,0.005448366,0.0003723907,0.0005732331,0.00007913057,0.0004202733,0.00103287,0.00003301927,0.001099243],"genre_scores_gemma":[0.9958134,0.001030379,0.0005323663,0.0003948239,0.00007658661,0.0002610963,0.001297293,0.0000066588,0.0005873251],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002701545,"threshold_uncertainty_score":0.01428735,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09016006363210953,"score_gpt":0.3858816295409379,"score_spread":0.2957215659088284,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}